Mutants of glycosyltransferases and related sugar nucleotide biosynthetic enzymes have been essential for in vitro glycorandomization to create libraries of novel glycosylated natural products and derivatives. These diverse glycorandomized compounds can now be produced in vivo economically by fermenting engineered Escherichia coli cells that express enzyme mutants.
No takes yet. Share an insight, caveat, or question.
Xi Chen (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: